Loading clinical trials...
Loading clinical trials...
A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Myeloid Malignancies
Conditions
Interventions
Magrolimab
Azacitidine
+5 more
Locations
21
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, California, United States
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
Los Angeles, California, United States
Stanford Cancer Center
Palo Alto, California, United States
Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Start Date
June 28, 2021
Primary Completion Date
March 4, 2024
Completion Date
March 4, 2024
Last Updated
March 20, 2025
NCT06090669
NCT06383572
NCT01366612
NCT06254742
NCT07052422
NCT06917105
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions